Lundbeck forges CNS pact with Zenobia, Vernalis

Denmark's Lundbeck has forged development pacts with Vernalis as well as Zenobia Therapeutics on an brain enzyme inhibition program designed to target CNS (central nervous system) ailments such as Parkinson's. Zenobia's technology will be used to crystallize and visualize the enzyme. "These collaborations are important supplements to Lundbeck's commitment to provide new, innovative medicines in the CNS field, in areas with high unmet needs," Lundbeck's Peter Hongaard Andersen, executive vice-president, research management, said in a statement. "It is this type of drug we expect will be in demand in the future." Report

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.